title: Adaptive resistance: a tumor strategy to evade immune attack.
abstract: A dilemma in cancer immunology is that, although patients often develop active antitumor immune responses, the tumor still outgrows. It has become clear that under the pressure of the host's immune system, cancer cells have adapted elaborate tactics to reduce their immunogenicity (also known as immunoselection) and/or to actively suppress immune cells and promote immune tolerance (also known as immunosubversion). In this issue of the European Journal of Immunology, Dolen and Esendagli [Eur. J. Immunol. 2013. 43: 747-757] show that acute myeloid leukemia (AML) cells develop an adaptive immune phenotype switching mechanism: In response to attack by activated T cells, the leukemia cells quickly downregulate the T-cell costimulatory ligand B7-H2 and reciprocally upregulate the coinhibitory ligands B7-H1 and B7-DC in order to shut down T-cell activation via the PD-1 pathway. These novel findings and their relevance for cancer immunotherapy, especially potential applications in PD-1 check-point blockade therapy are discussed in this Commentary.
authors: Department of Immunobiology and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT 06519, USA.
authors: Sheng
authors: S
authors: Yao
authors: Lieping
authors: L
authors: Chen
mesh_terms: D051940:B7-2 Antigen / Q000378:metabolism*; D006801:Humans; D007108:Immune Tolerance; D007951:Leukemia, Myeloid / Q000276:immunology* / Q000378:metabolism*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*
chemical_list: D051940:B7-2 Antigen
references: Nat Med. 2010 Apr;16(4):452-9
references: 20208540
references: Int Immunol. 1996 May;8(5):765-72
references: 8671665
references: J Exp Med. 2000 Oct 2;192(7):1027-34
references: 11015443
references: Nat Rev Immunol. 2004 May;4(5):336-47
references: 15122199
references: Nat Rev Immunol. 2008 Jun;8(6):467-77
references: 18500231
references: Blood. 2009 Jun 4;113(23):5811-8
references: 19339692
references: Br J Haematol. 1998 Sep;102(5):1257-62
references: 9753054
references: Nat Med. 2002 Aug;8(8):793-800
references: 12091876
references: Ann Hematol. 2005 May;84(5):287-97
references: 15592672
references: Br J Haematol. 2003 Feb;120(3):442-51
references: 12580958
references: Nat Med. 1999 Dec;5(12):1365-9
references: 10581077
references: Cancer Res. 2006 Apr 1;66(7):3381-5
references: 16585157
references: Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6198-203
references: 11983910
references: J Exp Med. 2001 Apr 2;193(7):839-46
references: 11283156
references: Sci Transl Med. 2012 Mar 28;4(127):127ra37
references: 22461641
references: N Engl J Med. 2012 Jun 28;366(26):2443-54
references: 22658127
references: Proc Natl Acad Sci U S A. 1990 Jul;87(13):5031-5
references: 2164219
references: J Exp Med. 1998 Dec 21;188(12):2205-13
references: 9858507
references: Immunity. 1994 Aug;1(5):405-13
references: 7882171
references: Immunity. 2011 May 27;34(5):729-40
references: 21530327
references: Nature. 2001 Jan 4;409(6816):97-101
references: 11343121
references: J Exp Med. 1995 Aug 1;182(2):459-65
references: 7543139
references: Nature. 2001 Jan 4;409(6816):102-5
references: 11343122
references: Nature. 1999 Dec 16;402(6763):827-32
references: 10617205
references: Nature. 1999 Jan 21;397(6716):263-6
references: 9930702
references: Clin Cancer Res. 2005 Aug 15;11(16):5708-17
references: 16115907
references: Eur J Immunol. 2013 Mar;43(3):747-57
references: 23175469
references: Nat Rev Immunol. 2006 Oct;6(10):715-27
references: 16977338
references: J Clin Oncol. 2010 Jul 1;28(19):3167-75
references: 20516446
references: Cancer Biol Ther. 2008 May;7(5):622-7
references: 18756622